How long has Mounjaro been on the market — and what does the timeline tell us?

Step 1 — years of clinical testing before Mounjaro reached a single pharmacy shelf

The question of how long tirzepatide has been on the market is actually two questions: how long it has been tested, and how long it has been available. Eli Lilly began the SURPASS diabetes trial programme in 2019, gathering safety and efficacy data across thousands of adults with type 2 diabetes. The SURMOUNT weight-management programme followed, with SURMOUNT-1 launching in late 2020 and running for 72 weeks. Results were published in the New England Journal of Medicine in 2022, showing average body-weight reductions of around 20–21% at the highest dose.

That's the evidence base regulators were reviewing when Mounjaro first reached patients. If you're curious about the depth of that pre-launch testing, the testing timeline for tirzepatide covers it in more detail.

One misconception that comes up fairly often: people assume a medicine this new must be experimental. In practice, Mounjaro completed one of the larger obesity-medicine trial programmes seen in recent years before a single prescription was written in the UK. The phase 3 evidence existed. The regulatory review took the time it needed to take.

Step 2, the UK licence and what it covers

The MHRA granted Mounjaro its UK marketing authorisation for weight management in November 2023. The licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. It also holds a separate licence for type 2 diabetes, which predates the weight-management approval, a point worth knowing if you've been reading about how long Mounjaro has been on the market for diabetes specifically.

Because Mounjaro is a newer medicine in real-world use, it carries a Black Triangle (▼) designation. This doesn't indicate a safety concern; it's a standard MHRA mechanism that prompts heightened post-authorisation monitoring and encourages healthcare professionals to report any suspected side effects. The NICE technology appraisal TA1026, published in December 2024 and updated in September 2025, formally recommended tirzepatide for NHS use under specific criteria, which added another layer of scrutiny to the evidence base.

Treatment starts at the 2.5 mg dose and is titrated by the prescriber, typically in four-week steps, up through 5, 7.5, 10, 12.5, and 15 mg. The 2.5 mg starting dose exists to help the body adjust gradually, not as a therapeutic target in its own right.

Step 3, how the evidence has developed since UK launch

Since the UK licence was granted, the evidence picture has continued to grow. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg in 751 adults with obesity over 72 weeks. Tirzepatide produced greater average weight reduction. That trial didn't exist when Mounjaro first became available in the UK; it's a product of the post-launch research environment, which is normal for medicines at this stage of their lifecycle.

For context on how the medicine has been used across a longer arc, the history of tirzepatide in clinical use spans both the diabetes and weight-management programmes. And if you're trying to understand what to expect week by week once treatment starts, the page on how long Mounjaro takes to work sets realistic timescales based on trial data.

The short answer on cost context: private treatment pricing has shifted since Eli Lilly raised its UK list price in September 2025. The Mounjaro cost page sets out what private prescriptions typically include and what to look for in a legitimate price.

Step 4, what the timeline means for someone starting treatment now

Starting Mounjaro now means starting it at a point where the evidence base is more complete than it was at launch. The phase 3 data existed before the UK licence; the head-to-head data against semaglutide, and the real-world safety information gathered under Black Triangle monitoring, have built on that foundation since.

What hasn't changed is the process for obtaining it lawfully. Mounjaro is a prescription-only medicine. The only legitimate route is a clinical assessment by a registered prescriber who can review your health history, current medicines, and suitability. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a named clinician, not an automated system. Our Mounjaro treatment page explains the process in full, and our weight-loss treatment overview covers the broader options if you're still deciding.

If you're ready to find out whether Mounjaro is clinically suitable for you, a free consultation is the place to start.